倍博特治疗轻中度老年原发性高血压的疗效及安全性观察

目的探讨倍博特治疗轻中度老年原发性高血压的疗效及安全性。方法选取本院2011年12月至2013年12月诊治的轻中度老年原发性高血压患者162例,采用数字随机法分为两组,81例患者采用缬沙坦治疗为对照组,81例患者采用倍博特治疗为观察组,比较两组患者的血压改变情况、临床疗效、不良反应情况。结果治疗后,两组患者舒张压、收缩压均显著下降,观察组患者舒张压、收缩压、不良反应发生率均明显低于对照组,观察组患者治疗总有效率明显高于对照组,差异均有统计学意义(P<0.05)。结论倍博特是治疗轻中度老年原发性高血压的有效药物,可明显降低患者的舒张压和收缩压,临床疗效显著且不良反应少,具有较高的安全性,值得临床推广使用。

Efficacy and Safety of Bebot for the Treatment of Elderly Patients with Mild or Moderate Primary Hypertension

Objective To investigate the efficacy and safety of bebot for the treatment of elderly patients with mild or moderate primary hypertension. Methods 162 elderly patients with mild or moderate primary hypertension in our hospital from December 2011 to December 2013 were selected and randomly divided into two groups, with 81 cases in each group. The control group was treated with valsartan, while the observation group was treated with bebot. The blood pressure changes, clinical effects and adverse reactions were compared between two groups. Results After treatment, diastolic blood pressure （DBP） and systolic blood pressure （SBP） decreased significantly in two groups. DBP, SBP and incidence of adverse reactions of observation group were significantly lower than those of control group. The total efficiency of observation group was significantly higher than that of control group. Differences were statistically significant （all P 〈0.05）. Conclusions Bebot is an effective drug for the treatment of elderly patients with mild or moderate primary hypertension, which can significantly reduce DBP and SBP. Bebot has significant clinical efficacy, with few adverse reactions and high safety.